Faga Daniel 4

4 · First Tracks Biotherapeutics, Inc. · Filed May 14, 2026

AI-generated summary of this filing

Updated May 14, 2026

First Tracks (TRAX) CEO Daniel Faga Receives RSUs and Option Grant

What Happened

Daniel Faga, President, CEO and Director of First Tracks Biotherapeutics (TRAX), was granted two derivative awards on May 12, 2026: 100,200 restricted stock units (RSUs) and an option award covering 271,100 shares. Both awards are reported at $0.00 acquisition price (awarded, not purchased), so there was no cash paid by the insider.

Key Details

Transaction date: May 12, 2026; Form 4 filed May 14, 2026 (appears timely under the 2-business-day rule).
Award specifics:
- 100,200 RSUs (each RSU converts to 1 share upon settlement) — footnote F1/F2.
- Option covering 271,100 shares — footnotes F3/F4.
Vesting:
- RSUs vest 25% annually beginning May 12, 2027 until fully vested (F2).
- The option vests 25% on May 12, 2027, then 1/48 of total shares monthly thereafter until fully vested (F3).
Shares owned after transaction: not specified in the provided excerpt; Form notes the Reporting Person also holds additional options to purchase up to 1,035,941 shares (F4).
Filing/timeliness: No late-filing indicator provided.

Context

These are compensation awards (derivative grants), not open-market purchases or sales. RSUs are a contingent right to receive shares at settlement for no consideration; options give the right to buy shares according to the stated vesting schedule.
Awards to executives are common for retention and performance incentives and do not reflect an immediate market transaction (no shares were sold or bought in the open market as part of this filing).

Form 4

Period: 2026-05-12

DirectorPresident, CEO

Transactions

Award
Restricted Stock Unit
[F1][F2]
2026-05-12+100,200→ 100,200 total
→ Common Stock (100,200 underlying)
Award
Employee Stock Option (right to buy)
[F3][F4]
2026-05-12+271,100→ 271,100 total
Exercise: $17.81Exp: 2036-05-11→ Common Stock (271,100 underlying)

Footnotes (4)

[F1]Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
[F2]The RSUs vests as to 25% of the total RSUs annually commencing on May 12, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
[F3]The stock option vests as to 25% of the total shares on May 12, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
[F4]In addition to the options to purchase a total of 271,100 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 1,035,941 shares of common stock, which options vest according to their terms.

Signature

/s/ Ajim Tamboli, Attorney-in-Fact|2026-05-14

1 file